MedTrace Logo

Assess Cancer in Ovarian Tumors With Biomarkers.

NCT00436189 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2008-04-30

No results posted yet for this study

Summary

Purpose

The OvaRI assay clinical trial is directed at evaluating a novel proteomics-based blood test. This test is for a physician to use towards differentiating benign from malignant ovarian tumors prior to surgical intervention. Tools that can better triage women with an ovarian tumor are needed. It has been shown that women with ovarian cancer who are referred to gynecologic oncologists have better outcomes. The primary objective of this study is to demonstrate that the OvaRl assay (test) improves the preoperative identification of ovarian cancer in patients with a ovarian tumor.

Conditions

  • Ovarian Tumor

Interventions

PROCEDURE

Blood Draw

Sponsors & Collaborators

  • Ciphergen Biosystems

    lead INDUSTRY

Principal Investigators

  • Gillian Crutcher · Ciphergen Biosystems, Inc.

  • Fred Ueland, M.D. · University of Kentucky

  • Eric Fung, M.D. · CSO Ciphergen Biosystems

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2008-04-30
Completion
2008-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00436189 on ClinicalTrials.gov